Agenus (AGEN) Debt/Equity Ratio: History & Chart

Agenus Inc.(AGEN)

Biotechnology · Lexington, MA

$7.61-1.13 (-12.89%)

Delayed quote: Oct 6, 2026, 2:10 PM EDT

About Agenus Inc.

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Lexington, MA

81 employees

www.agenusbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Garo H. Armen

View full financials

AGEN Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

-0.20

DEBT TO EQUITY RATIO AVG TTM

-0.65

DEBT TO EQUITY RATIO AVG 3Y

-0.73

DEBT TO EQUITY RATIO AVG 5Y

-0.72

DEBT TO EQUITY RATIO AVG 10Y

-0.58

DEBT TO EQUITY RATIO AVG 15Y

-0.80

DEBT TO EQUITY RATIO AVG 20Y

-1.18

CURRENT VS TTM AVG

+68.43%

CURRENT VS 3Y AVG

+72.04%

CURRENT VS 5Y AVG

+71.78%

CURRENT VS 10Y AVG

+64.61%

CURRENT VS 15Y AVG

+74.54%

CURRENT VS 20Y AVG

+82.69%

SECTOR MEDIAN · HEALTHCARE

0.11

median of 765 covered companies

CURRENT VS SECTOR MEDIAN

-285.90%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Agenus Inc. (AGEN)	$316.69M	-0.20	-0.65	-0.73	-0.72
Avita Medical Inc. (RCEL)vs ›	$320.20M	N/A	5.54	2.78	1.86
ClearPoint Neuro, Inc. (CLPT)vs ›	$320.89M	5.93	1.11	0.80	2.27
Sanara MedTech Inc. (SMTI)vs ›	$321.67M	6.11	4.48	2.31	1.55
Cabaletta Bio, Inc. (CABA)vs ›	$322.03M	0.12	0.17	0.10	0.07
C4 Therapeutics, Inc. (CCCC)vs ›	$313.46M	0.23	0.27	0.28	0.22
CapsoVision, Inc. (CV)vs ›	$325.51M	0.05	0.07	0.07	0.07
Mobia Medical, Inc. Common Stock (MOBI)vs ›	$303.72M	0.05	N/A	N/A	N/A
Benitec Biopharma Inc. (BNTC)vs ›	$303.15M	0.00	0.01	0.70	0.51
Larimar Therapeutics, Inc. (LRMR)vs ›	$291.63M	0.04	0.04	0.05	0.06

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Agenus Inc. (AGEN)

$316.69M

-0.20

-0.65

-0.73

-0.72

Avita Medical Inc. (RCEL)vs ›

$320.20M

N/A

5.54

2.78

1.86

ClearPoint Neuro, Inc. (CLPT)vs ›

$320.89M

5.93

1.11

0.80

2.27

Sanara MedTech Inc. (SMTI)vs ›

$321.67M

6.11

4.48

2.31

1.55

Cabaletta Bio, Inc. (CABA)vs ›

$322.03M

0.12

0.17

0.10

0.07

C4 Therapeutics, Inc. (CCCC)vs ›

$313.46M

0.23

0.27

0.28

0.22

CapsoVision, Inc. (CV)vs ›

$325.51M

0.05

0.07

Mobia Medical, Inc. Common Stock (MOBI)vs ›

$303.72M

0.05

N/A

Benitec Biopharma Inc. (BNTC)vs ›

$303.15M

0.00

0.01

0.70

0.51

Larimar Therapeutics, Inc. (LRMR)vs ›

$291.63M

0.04

0.05

0.06

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Agenus Inc. (AGEN)?

The debt to equity ratio for AGEN stock is -0.20.

Is Agenus Inc.'s debt to equity ratio high or low?

The debt to equity ratio of -0.20 is 72% above its 5-year average of -0.72, near the low end of its 5-year range (-3.88–23.47).

What is the TTM average debt to equity ratio for Agenus Inc. (AGEN)?

The TTM average debt to equity ratio for AGEN stock is -0.65.

What is the 3Y average debt to equity ratio for Agenus Inc. (AGEN)?

The 3Y average debt to equity ratio for AGEN stock is -0.73.

What is the 5Y average debt to equity ratio for Agenus Inc. (AGEN)?

The 5Y average debt to equity ratio for AGEN stock is -0.72.

What is the 10Y average debt to equity ratio for Agenus Inc. (AGEN)?

The 10Y average debt to equity ratio for AGEN stock is -0.58.

What is the 15Y average debt to equity ratio for Agenus Inc. (AGEN)?

The 15Y average debt to equity ratio for AGEN stock is -0.80.

What is the 20Y average debt to equity ratio for Agenus Inc. (AGEN)?

The 20Y average debt to equity ratio for AGEN stock is -1.18.

DATE	DEBT TO EQUITY RATIO
2026-06-30	-0.20
2026-03-31	-1.38
2025-12-31	-1.24
2025-09-30	-0.17
2025-06-30	-0.26
2025-03-31	-0.27
2024-12-31	-0.29
2024-09-30	-1.44
2024-06-30	-0.34
2024-03-31	-1.73
2023-12-31	-0.58
2023-09-30	-0.69
2023-06-30	-0.94
2023-03-31	-1.50
2022-12-31	-1.28
2022-09-30	-3.88
2022-06-30	23.47
2022-03-31	4.09
2021-12-31	1.69
2021-09-30	1.30
2021-06-30	-1.34
2021-03-31	-1.79
2020-12-31	-0.27
2020-09-30	-0.19
2020-06-30	-0.17
2020-03-31	-0.15
2019-12-31	-0.10
2019-09-30	-0.12
2019-06-30	-0.14
2019-03-31	-0.18
2018-12-31	-0.08
2018-09-30	-0.10
2018-06-30	-0.12
2018-03-31	-0.11
2017-12-31	-2.15
2017-09-30	-2.78
2017-06-30	-7.93
2017-03-31	15.08
2016-12-31	-3.34
2016-09-30	-6.01
2016-06-30	7.24
2016-03-31	2.66
2015-12-31	1.62
2015-09-30	1.44
2015-06-30	0.13
2015-03-31	0.25
2014-12-31	0.26
2014-09-30	0.14
2014-06-30	0.13
2014-03-31	0.15
2013-12-31	-1.98
2013-09-30	-3.24
2013-06-30	-0.53
2013-03-31	-1.60
2012-12-31	-2.04
2012-09-30	-2.70
2012-06-30	-2.08
2012-03-31	-2.05
2011-12-31	-1.25
2011-09-30	-1.94
2011-06-30	-1.78
2011-03-31	-2.32
2010-12-31	-2.33
2010-09-30	-1.98
2010-06-30	-2.50
2010-03-31	-2.05
2009-12-31	-2.92
2009-09-30	-2.54
2009-06-30	-1.71
2009-03-31	-2.06
2008-12-31	-2.84
2008-09-30	-2.63
2008-06-30	-3.95
2008-03-31	-2.54
2007-12-31	-1.65
2007-09-30	-1.94
2007-06-30	-2.22
2007-03-31	-3.00
2006-12-31	-4.34
2006-09-30	-7.22
2006-06-30	16.81
2006-03-31	3.28
2005-12-31	0.13
2005-09-30	1.12
2005-06-30	0.85
2005-03-31	0.66
2004-12-31	0.09
2004-09-30	0.09
2004-06-30	0.09
2004-03-31	0.10
2003-12-31	0.15
2003-09-30	0.10
2003-06-30	0.00
2003-03-31	0.00
2002-12-31	0.01
2002-09-30	0.01

DATE

DEBT TO EQUITY RATIO

2026-06-30

-0.20

2026-03-31

-1.38

2025-12-31

-1.24

2025-09-30

-0.17

2025-06-30

-0.26

2025-03-31

-0.27

2024-12-31

-0.29

2024-09-30

-1.44

2024-06-30

-0.34

2024-03-31

-1.73

2023-12-31

-0.58

2023-09-30

-0.69

2023-06-30

-0.94

2023-03-31

-1.50

2022-12-31

-1.28

2022-09-30

-3.88

2022-06-30

23.47

2022-03-31

4.09

2021-12-31

1.69

2021-09-30

1.30

2021-06-30

-1.34

2021-03-31

-1.79

2020-12-31

-0.27

2020-09-30

-0.19

2020-06-30

-0.17

2020-03-31

-0.15

2019-12-31

-0.10

2019-09-30

-0.12

2019-06-30

-0.14

2019-03-31

-0.18

2018-12-31

-0.08

2018-09-30

-0.10

2018-06-30

-0.12

2018-03-31

-0.11

2017-12-31

-2.15

2017-09-30

-2.78

2017-06-30

-7.93

2017-03-31

15.08

2016-12-31

-3.34

2016-09-30

-6.01

2016-06-30

7.24

2016-03-31

2.66

2015-12-31

1.62

2015-09-30

1.44

2015-06-30

0.13

2015-03-31

0.25

2014-12-31

0.26

2014-09-30

0.14

2014-06-30

0.13

2014-03-31

0.15

2013-12-31

-1.98

2013-09-30

-3.24

2013-06-30

-0.53

2013-03-31

-1.60

2012-12-31

-2.04

2012-09-30

-2.70

2012-06-30

-2.08

2012-03-31

-2.05

2011-12-31

-1.25

2011-09-30

-1.94

2011-06-30

-1.78

2011-03-31

-2.32

2010-12-31

-2.33

2010-09-30

-1.98

2010-06-30

-2.50

2010-03-31

-2.05

2009-12-31

-2.92

2009-09-30

-2.54

2009-06-30

-1.71

2009-03-31

-2.06

2008-12-31

-2.84

2008-09-30

-2.63

2008-06-30

-3.95

2008-03-31

-2.54

2007-12-31

-1.65

2007-09-30

-1.94

2007-06-30

-2.22

2007-03-31

-3.00

2006-12-31

-4.34

2006-09-30

-7.22

2006-06-30

16.81

2006-03-31

3.28

2005-12-31

0.13

2005-09-30

1.12

2005-06-30

0.85

2005-03-31

0.66

2004-12-31

0.09

2004-09-30

0.09

2004-06-30

0.09

2004-03-31

0.10

2003-12-31

0.15

2003-09-30

0.10

2003-06-30

0.00

2003-03-31

0.00

2002-12-31

0.01

2002-09-30

0.01

Debt to Equity Ratio: -0.20

AGEN Debt to Equity Ratio

AGEN Average Debt to Equity Ratio Chart

AGEN Current vs Average Debt to Equity Ratio Chart

AGEN Debt to Equity Ratio Metrics

AGEN Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

AGEN Debt to Equity Ratio History

Related Metrics